Hogan Lovells 2024 Election Impact and Congressional Outlook Report
Imogen Ireland
Senior Associate Intellectual Property
Imogen’s contentious work is complimented by her non-contentious work which focuses on the assessment of individual patents and portfolios for the purposes of licensing or asserting. As part of this, she has advised on strategies for novel technologies using artificial intelligence and digital diagnostic tools.
Imogen has written widely on the topic of artificial intelligence and its projected impact on intellectual property. At present, she is advising clients on AI-specific issues to do with AI-derived IP, liability and enforcement considerations.
Imogen graduated from the University of Cambridge. Following qualification as a lawyer, she completed the Postgraduate Diploma in Intellectual Property Law and Practice at the University of Oxford with a Distinction.
Acting for HTC Corporation in UK patent infringement and revocation proceedings against Nokia, including coordination with parallel patent actions across Europe.
Acting for Thoratec in multijurisdictional patent litigation against AIS in relation to ventricular assist devices.
Acting for Anan Kasei in patent infringement and revocation proceedings against Molycorp, including coordination with parallel patent actions across Europe.
Acting for a global telecommunications company in UK litigation concerning standard essential patents, including coordination with European, ITC and EPO proceedings.
Advising an innovator on its IP and regulatory strategy for protecting medicinal products discovered using artificial intelligence.
Advising on the purchase of royalty revenue streams for a pan-European portfolio of patents relating to a medicinal product.
Representing HTC in multiple litigations in the UK, including against Philips and against Nokia in UK litigation.
Acting for various companies involved in the manufacture and distribution of inflight entertainment systems in relation to an action for the recovery of damages as against those companies.
Acting for BMS in relation to patent challenges around its products ELIQUIS® (apixaban) and SPRYCEL® (dasatinib) (High Court and Court of Appeal).
Acting for Anan Kasei BMS in relation to patent challenges and recovery of damages around its metal oxide product (High Court and Court of Appeal).